Multicenter validation study of a treatment selection MAP for pancreatic neuroendocrine tumors.

ABSTRACT:

Background

Somatostatin analogs, molecular-targeted agents and cytotoxic anticancer agents are available as therapeutic agents for the systemic treatment of pancreatic neuroendocrine tumors, and we have developed a first-line treatment selection MAP to enable selection of the optimal treatment strategy for pancreatic neuroendocrine tumors. The purpose of this study was to validate the usefulness of the treatment selection MAP.

Methods

Patients who had received systemic therapy for a pancreatic neuroendocrine tumor between January 2017 and December 2020 were compared according to whether they had been treated as recommended by the MAP (matched patients) or not (unmatched patients) to determine whether better outcomes were achieved by the matched patients. The primary endpoint

SUBMITTER: Ikeda M 

PROVIDER: S-EPMC11322880 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature